KR20090015980A - (트랜스-4-[(〔5-[(3,4-디플루오로페닐)아미노]-1,3,4-옥사디아졸-2-일〕카르보닐)아미노]페닐〕시클로헥실)아세트산의 결정형 - Google Patents

(트랜스-4-[(〔5-[(3,4-디플루오로페닐)아미노]-1,3,4-옥사디아졸-2-일〕카르보닐)아미노]페닐〕시클로헥실)아세트산의 결정형 Download PDF

Info

Publication number
KR20090015980A
KR20090015980A KR1020087030959A KR20087030959A KR20090015980A KR 20090015980 A KR20090015980 A KR 20090015980A KR 1020087030959 A KR1020087030959 A KR 1020087030959A KR 20087030959 A KR20087030959 A KR 20087030959A KR 20090015980 A KR20090015980 A KR 20090015980A
Authority
KR
South Korea
Prior art keywords
amino
phenyl
cyclohexyl
trans
acetic acid
Prior art date
Application number
KR1020087030959A
Other languages
English (en)
Korean (ko)
Inventor
앤드루 혼비 답슨
월터 그룬디
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20090015980A publication Critical patent/KR20090015980A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
KR1020087030959A 2006-06-12 2007-06-08 (트랜스-4-[(〔5-[(3,4-디플루오로페닐)아미노]-1,3,4-옥사디아졸-2-일〕카르보닐)아미노]페닐〕시클로헥실)아세트산의 결정형 KR20090015980A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0611552.1 2006-06-12
GBGB0611552.1A GB0611552D0 (en) 2006-06-12 2006-06-12 Chemical compounds

Publications (1)

Publication Number Publication Date
KR20090015980A true KR20090015980A (ko) 2009-02-12

Family

ID=36745696

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087030959A KR20090015980A (ko) 2006-06-12 2007-06-08 (트랜스-4-[(〔5-[(3,4-디플루오로페닐)아미노]-1,3,4-옥사디아졸-2-일〕카르보닐)아미노]페닐〕시클로헥실)아세트산의 결정형

Country Status (16)

Country Link
EP (1) EP2041101A1 (fr)
JP (1) JP2009539954A (fr)
KR (1) KR20090015980A (fr)
CN (1) CN101466690A (fr)
AR (1) AR061332A1 (fr)
AU (1) AU2007259031A1 (fr)
BR (1) BRPI0712354A2 (fr)
CA (1) CA2653550A1 (fr)
CL (1) CL2007001700A1 (fr)
GB (1) GB0611552D0 (fr)
IL (1) IL195348A0 (fr)
MX (1) MX2008015762A (fr)
NO (1) NO20084963L (fr)
TW (1) TW200815378A (fr)
UY (1) UY30404A1 (fr)
WO (1) WO2007144571A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588162A1 (fr) 2004-12-14 2006-06-22 Astrazeneca Ab Derives d'oxadiazole en tant qu'inhibiteurs de dgat
EP1966221A1 (fr) 2005-12-22 2008-09-10 AstraZeneca AB Pyrimido-[4,5-]-oxazines pour utilisation en tant qu'inhibiteurs de dgat
EP2402318A1 (fr) 2006-03-31 2012-01-04 Novartis AG Inhibiteurs de la DGAT
NZ572585A (en) 2006-05-30 2011-02-25 Astrazeneca Ab 1,3,4-Oxadiazole derivatives as DGAT1 inhibitors
BRPI0712802A2 (pt) 2006-05-30 2012-10-23 Astrazeneca Ab composto, métodos para produzir uma inibição da atividade de dgat1, e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para preparar um composto
EP2120911A1 (fr) * 2007-02-15 2009-11-25 Prosidion Limited Dérivés d'amide et d'urée pour le traitement de maladies métaboliques
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
JP5662803B2 (ja) 2007-12-20 2015-02-04 アストラゼネカ アクチボラグ Ｄｇａｔ１阻害剤としてのカルバモイル化合物１９０
EP2805951B1 (fr) 2009-03-20 2018-03-14 Metabasis Therapeutics, Inc. Inhibiteurs de diacylglycérol o-acétyltransférase 1 (dgat-1) et leurs utilisations
MX2011014018A (es) 2009-06-19 2012-02-22 Astrazeneca Ab Pirazincarboxamidas como inhibidores de dgati.
FR2963005B1 (fr) * 2010-07-23 2012-08-17 Sanofi Aventis Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
CA2588162A1 (fr) * 2004-12-14 2006-06-22 Astrazeneca Ab Derives d'oxadiazole en tant qu'inhibiteurs de dgat

Also Published As

Publication number Publication date
CN101466690A (zh) 2009-06-24
IL195348A0 (en) 2009-08-03
WO2007144571A1 (fr) 2007-12-21
NO20084963L (no) 2009-01-07
JP2009539954A (ja) 2009-11-19
BRPI0712354A2 (pt) 2012-06-05
MX2008015762A (es) 2009-03-16
CL2007001700A1 (es) 2008-01-18
AR061332A1 (es) 2008-08-20
AU2007259031A1 (en) 2007-12-21
TW200815378A (en) 2008-04-01
EP2041101A1 (fr) 2009-04-01
CA2653550A1 (fr) 2007-12-21
UY30404A1 (es) 2008-01-31
GB0611552D0 (en) 2006-07-19

Similar Documents

Publication Publication Date Title
KR20090015980A (ko) (트랜스-4-[(〔5-[(3,4-디플루오로페닐)아미노]-1,3,4-옥사디아졸-2-일〕카르보닐)아미노]페닐〕시클로헥실)아세트산의 결정형
KR20090012349A (ko) 아세틸 조효소 ａ 디아실글리세롤 아실트랜스퍼라제의 억제제로서의 치환된 5-페닐아미노-1,3,4-옥사디아졸-2-일카르보닐아미노-4-페녹시-시클로헥산 카르복실산
KR20090010092A (ko) Ｄｇａｔ1 억제제로서의 1,3,4-옥사디아졸 유도체
EP0996618B1 (fr) Antagonistes de l'endotheline: n- 2'- 4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl) 1,1'-biphenyl]-2-yl]methyl]-n,3,3-trimethylbutanamide et n-(4,5-dimethyl-3-isoxazolyl)-2'- 3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl) 1,1'-biphenyl]-2-sulfonamide et leurs sels
AU2003297232B2 (en) 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles
JP2023011677A (ja) γ－ヒドロキシ酪酸（ＧＨＢ）のプロドラッグ、その組成物および使用
EP2035417B1 (fr) Benzimidazoles et leur application au traitement du diabète
CA3085561A1 (fr) Azines triazoles d'acide cyclohexyle utilisees en tant qu'antagonistes de lpa
JP2008543747A (ja) Ｄｇａｔ阻害剤としてのオキサジアゾール誘導体
JP2009520786A (ja) Ｄｇａｔ阻害剤として使用するためのピリミド−［４，５−ｂ］−オキサジン
JP2009539957A (ja) Ｄｇａｔ１の活性を阻害させるための化合物
CA3059107A1 (fr) Composes inhibiteurs d'ask1 et utilisations associees
KR20030074774A (ko) 접합 헤테로시클릭 화합물
KR20100099738A (ko) Ｄｇａｔ1 억제제로서의 카르바모일 화합물 190
IL104748A (en) History of isoxalil sulfonamide and pharmaceutical preparations containing them
KR20120088738A (ko) 칼슘 방출-활성화 칼슘 통로의 조정제로서의 피라졸 유도체
MXPA97002658A (en) Novedous derivatives of carboxyl acid, supreparation and
KR20110102910A (ko) 1,3,4-옥사디아졸 유도체 및 당뇨병의 치료를 위한 이의 용도
WO2008129319A1 (fr) Sel de dérivés d'oxadiazole comme inhibiteurs de dgat
CA2168154A1 (fr) Derives de substitution biphenyliques de sulfonamide, antagonistes de l'endotheline
CA2681861A1 (fr) Derive de l'ornithine
KR20180021820A (ko) Ido 억제제
EP2190840A2 (fr) Composés chimiques 979
KR20100137567A (ko) Ｊｎｋ 의 억제제
CN118026948A (zh) 三联芳环类化合物及其制备方法、药物组合物和应用

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid